{"schema_version":"secwatch.filing_event.v1","accession":"0000879169-25-000115","form_type":"8-K","ticker":"INCY","cik":"0000879169","company_name":"INCYTE CORP","filed_at":"2025-10-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:42.441242+00:00","generated_at":"2026-05-17T02:05:29.921877+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Incyte Q3 revenue $1.37B (+20% YoY); raises FY 2025 product revenue guidance to $4.23-4.32B","bullets":["GAAP diluted EPS $2.11 vs $0.54 YoY; Non-GAAP diluted EPS $2.26 vs $1.07.","Jakafi net revenue $791M (+7%), Opzelura $188M (+35%), Niktimvo $46M (launch).","Raised FY 2025 Jakafi guidance to $3.05-3.075B, other oncology to $550-575M.","FDA approved Opzelura for pediatric atopic dermatitis (age 2+).","Plan to start registrational program for INCA33890 in MSS CRC in 2026; paused INCA034460, INCB57643, povorcitinib in CSU."],"urls":{"canonical":"https://secwatch.observer/filing/0000879169-25-000115","json":"https://secwatch.observer/filing/0000879169-25-000115.json","markdown":"https://secwatch.observer/filing/0000879169-25-000115.md","text":"https://secwatch.observer/filing/0000879169-25-000115.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/879169/000087916925000115/0000879169-25-000115-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/879169/000087916925000115/incy-20251028.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T02:05:29.921877+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}